CryoPort Aktie News

NASHVILLE, Tenn. , April 30, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in supply chain solutions for cell & gene therapies, today announced that the Company will report financial results for the first quarter ended March 31, 2024 on Tuesday, May 7, 2024 after U.S. markets close.

Cryoport, Inc. (CYRX) Q4 2023 Earnings Call Transcript

FY 2023 revenue of $233.3 million, in-line with guidance Year-over-year, Commercial Cell & Gene Therapy revenue rose 33%; BioStorage/BioServices revenue increased 45% Global clinical trials supported reached a record 675 NASHVILLE, Tenn., March 12, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for cell & gene therapies, today announce...

NASHVILLE, Tenn. , Feb. 27, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in supply chain solutions for cell & gene therapies, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2023 on Tuesday, March 12, 2024 after U.S. markets close.

Companies Will Partner to Provide Complete Supply Chain Solutions for the Life Science and Biopharmaceutical Industries NASHVILLE, Tenn. , Nov. 27, 2023 /PRNewswire/ -- Cryoport Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life s...

CRYOPDP's Acquisition of Bluebird Express Adds Further Domestic and International Transportation Services Strengthening CRYOPDP's U.S. Logistics Operations NASHVILLE, Tenn. , Nov. 16, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the futur...

Cryoport, Inc. (NASDAQ:CYRX ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Todd Fromer - Investor Relations Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Thomas Heinzen - Vice President, Corporate Development and Investor Relations Conference Call Participants Paul Knight - KeyB...

Third quarter 2023 commercial Cell and Gene Therapy revenue up 54% year-over-year Supporting a record total of 670 clinical trials worldwide, with 81 in Phase 3 Nine months 2023 revenue of $176 million Affirms full year 2023 revenue guidance of $233 - $243 million NASHVILLE, Tenn. , Nov. 8, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provid...